These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15066080)

  • 1. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
    Arora A; Potter JF
    J Am Geriatr Soc; 2004 Apr; 52(4):611-6. PubMed ID: 15066080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
    Herold CI; Blackwell KL
    Clin Breast Cancer; 2008 Feb; 8(1):50-64. PubMed ID: 18501059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
    Buzdar AU
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):623-9. PubMed ID: 12503208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current status of aromatase inhibitors in the management of breast cancer.
    Baum M; Buzdar A
    Surg Clin North Am; 2003 Aug; 83(4):973-94. PubMed ID: 12875605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant endocrine therapy for breast cancer: past, present and future.
    Barnadas A; Gil M; Sánchez-Rovira P; Llombart A; Adrover E; Estevez LG; de la Haba J; Calvo L
    Anticancer Drugs; 2008 Apr; 19(4):339-47. PubMed ID: 18454044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving uses of hormonal agents for breast cancer therapy.
    Cummings FJ
    Clin Ther; 2002; 24 Suppl C():C3-25. PubMed ID: 12117074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
    Lindberg H; Nielsen DL; Tuxen M; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3096-100. PubMed ID: 17877958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advancement in endocrine therapy for breast cancer].
    Yang MT; Lian ZQ
    Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.